Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Glucocorticoid-Resistant or Intolerant Moderate-to-Severe Active Thyroid Eye Disease
NCT07547930Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in thyroid eye disease (TED), sponsored by First Affiliated Hospital of Xiamen University. Started Apr 2026; status: recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07547930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547930.